Contract manufacturing organizations (CMOs) and contract research organizations (CROs). Global sourcing of pharma ingredients and services. Trends and challenges for the biopharmaceutical and pharmaceutical industries.
November 19, 2009 ePT--the Electronic Newsletter of Pharmaceutical Technology
Company and People Notes: Genzyme provides updates on enzyme replacement products and FDA complete response letter; Watson appoints VP of global operations; more...
 |
November 12, 2009 ePT--the Electronic Newsletter of Pharmaceutical Technology
Company and People Notes: 3M forms agreement with VaxInnate; TRIN Pharma appoints CEO; More...
 |
November 5, 2009 ePT--the Electronic Newsletter of Pharmaceutical Technology
Company and People Notes: sanofi aventis forms pact with Micromet; Laureate Pharma adds members to its business team.
 |
November 5, 2009 By:Patricia Van Arnum ePT--the Electronic Newsletter of Pharmaceutical Technology
Lonza (Basel, Switzerland), the large contract manufacturer of small-molecule and biologic-based active pharmaceutical ingredients (APIs), announced last week a series of cost-cutting measures for the next 12 to 18 months.
 |
November 2, 2009 By:Michelle Hoffman Pharmaceutical Technology
While Congress debates hundreds of healthcare plan proposals, perhaps we, the public, can get in the game too.
 |
 | November 2, 2009 By:Angie Drakulich Pharmaceutical Technology
A panel of industry and regulatory experts, including FDA, discuss efforts to secure the global pharmaceutical supply chain. This article contains bonus online-exclusive material.
 |
 | November 2, 2009 By:Jane Wan Pharmaceutical Technology
New pricing controls and healthcare reforms may be pushing the pharmaceutical market out of this southeast Asian country. This article contains bonus online-exclusive material.
 |
November 2, 2009 By:Jim Miller Pharmaceutical Technology
Contract organizations waiting for the pipeline to come roaring back are kidding themselves.
 |
November 2, 2009 By:Angie Drakulich Pharmaceutical Technology
FDA's Edwin Rivera-Martinez on dodging supply-chain challenges.
 |
|